Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 39

1.

PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol.

Merat S, Poustchi H, Hemming K, Jafari E, Radmard AR, Nateghi A, Shiravi Khuzani A, Khoshnia M, Marshall T, Malekzadeh R.

Arch Iran Med. 2015 Aug;18(8):515-23. doi: 015188/AIM.009.

2.

National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.

Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP, Brown WV.

J Clin Lipidol. 2015 Mar-Apr;9(2):129-69. doi: 10.1016/j.jacl.2015.02.003. Epub 2015 Apr 7.

PMID:
25911072
3.

Frequency of high-risk patients not receiving high-potency statin (from a large managed care database).

Rodriguez F, Olufade T, Heithoff K, Friedman HS, Navaratnam P, Foody JM.

Am J Cardiol. 2015 Jan 15;115(2):190-5. doi: 10.1016/j.amjcard.2014.10.021. Epub 2014 Oct 30.

PMID:
25432414
5.

Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets.

Toth PP, Grabner M, Punekar RS, Quimbo RA, Cziraky MJ, Jacobson TA.

Atherosclerosis. 2014 Aug;235(2):585-91. doi: 10.1016/j.atherosclerosis.2014.05.914. Epub 2014 May 22.

6.

[Dose-dependent effect of atorvastatin on erectile function and androgen status in men with high cardiovascular risk].

Iakovenko EI, Evdakimova AA, Toguzova ZA, Sharvadze GG, Mamedov MN.

Kardiologiia. 2014;54(2):37-42. Russian.

PMID:
24888199
7.

Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.

Marrett E, Zhao C, Zhang NJ, Zhang Q, Ramey DR, Tomassini JE, Tershakovec AM, Neff DR.

Vasc Health Risk Manag. 2014 Apr 25;10:237-46. doi: 10.2147/VHRM.S54886. eCollection 2014.

8.

LDL-C levels in US patients at high cardiovascular risk receiving rosuvastatin monotherapy.

Ashton V, Zhang Q, Zhang NJ, Zhao C, Ramey DR, Neff D, Tershakovec AM, Marrett E.

Clin Ther. 2014 May;36(5):792-9. doi: 10.1016/j.clinthera.2014.03.010. Epub 2014 Apr 24.

PMID:
24768187
9.

Echolucency of carotid plaque is useful for assessment of residual cardiovascular risk in patients with chronic coronary artery disease who achieve LDL-C goals on statin therapy.

Uematsu M, Nakamura T, Sugamata W, Kitta Y, Fujioka D, Saito Y, Kawabata K, Obata JE, Watanabe Y, Watanabe K, Kugiyama K.

Circ J. 2014;78(1):151-8. Epub 2013 Nov 12.

10.

Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease.

Nestel PJ, Barnes EH, Tonkin AM, Simes J, Fournier M, White HD, Colquhoun DM, Blankenberg S, Sullivan DR.

Arterioscler Thromb Vasc Biol. 2013 Dec;33(12):2902-8. doi: 10.1161/ATVBAHA.113.302479. Epub 2013 Oct 3.

11.

High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?

Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, Nasir K, Blumenthal RS, Budoff MJ.

J Am Coll Cardiol. 2013 Jul 30;62(5):397-408. doi: 10.1016/j.jacc.2013.05.016. Epub 2013 May 30. Review.

12.

Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic.

Rollefstad S, Kvien TK, Holme I, Eirheim AS, Pedersen TR, Semb AG.

Ann Rheum Dis. 2013 Dec;72(12):1968-74. doi: 10.1136/annrheumdis-2012-202789. Epub 2012 Dec 22.

PMID:
23264359
13.

Systems biology analysis unravels the complementary action of combined rosuvastatin and ezetimibe therapy.

Verschuren L, Radonjic M, Wielinga PY, Kelder T, Kooistra T, van Ommen B, Kleemann R.

Pharmacogenet Genomics. 2012 Dec;22(12):837-45. doi: 10.1097/FPC.0b013e328359d274.

PMID:
23086299
14.

Efficacy of fix dose combination (atorvastatin and amlodipine) in treatment of uncontrolled hypertension and dyslipidemia.

Bashir S, Sherwani MU, Shabbir I, Batool A.

J Ayub Med Coll Abbottabad. 2011 Jul-Sep;23(3):97-100.

PMID:
23272446
15.
16.

Implementation of cardiovascular secondary prevention guidelines in clinical practice: a nationwide survey in Italy.

Perrone-Filardi P, Poli A, Ambrosio G, Proto C, Chimini C, Chiariello M.

Nutr Metab Cardiovasc Dis. 2012 Feb;22(2):149-53. doi: 10.1016/j.numecd.2010.05.009. Epub 2010 Sep 28.

PMID:
20875948
17.

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.

Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, Mora S, MacFadyen JG, Glynn RJ, Kastelein JJ; JUPITER Trial Study Group.

Lancet. 2010 Jul 31;376(9738):333-9. doi: 10.1016/S0140-6736(10)60713-1. Epub 2010 Jul 23.

PMID:
20655105
18.

Utility of Lp-PLA2 in lipid-lowering therapy.

Racherla S, Arora R.

Am J Ther. 2012 Mar;19(2):115-20. doi: 10.1097/MJT.0b013e3181e70d32. Review.

PMID:
20634673
19.

Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes.

Mandosi E, Fallarino M, Gatti A, Carnovale A, Rossetti M, Lococo E, Buchetti B, Filetti S, Lenti L, Morano S.

J Atheroscler Thromb. 2010 Jun 30;17(6):539-45. Epub 2010 Feb 5.

20.

Apolipoprotein measurements: is more widespread use clinically indicated?

Davidson MH.

Clin Cardiol. 2009 Sep;32(9):482-6. doi: 10.1002/clc.20559. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk